Last $20.52 USD
Change Today -0.275 / -1.32%
Volume 33.4K
LJPC On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 10:52 AM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

la jolla pharmaceutical co (LJPC) Snapshot

Open
$20.84
Previous Close
$20.79
Day High
$21.43
Day Low
$20.04
52 Week High
01/30/15 - $22.80
52 Week Low
05/23/14 - $6.17
Market Cap
312.4M
Average Volume 10 Days
99.8K
EPS TTM
$-16.01
Shares Outstanding
15.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for LA JOLLA PHARMACEUTICAL CO (LJPC)

la jolla pharmaceutical co (LJPC) Related Bloomberg News

View More Bloomberg News

la jolla pharmaceutical co (LJPC) Related Businessweek News

No Related Businessweek News Found

la jolla pharmaceutical co (LJPC) Details

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for chronic organ failure and cancer. The company’s products include GCS-100 that is in Phase II clinical trial for the treatment of chronic kidney disease. It also provides LJPC-501, a peptide agonist of the renin-angiotensin system, which is designed to help restore kidney function in patients with hepatorenal syndrome; and LJPC-401, a peptide for the treatment of iron disorders. La Jolla Pharmaceutical Company was founded in 1989 and is headquartered in San Diego, California.

7 Employees
Last Reported Date: 03/31/14
Founded in 1989

la jolla pharmaceutical co (LJPC) Top Compensated Officers

Chief Executive Officer, President, Principal...
Total Annual Compensation: $420.0K
Compensation as of Fiscal Year 2013.

la jolla pharmaceutical co (LJPC) Key Developments

La Jolla Pharmaceutical Company Announces Special Protocol Assessment for its Phase 3 Trial of LJPC-501

La Jolla Pharmaceutical Company announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assesment (SPA) for its Phase 3 clinical trial of LJPC-501 for the treatment of catecholamine-resistant hypotension (CRH). In accordance with the SPA, the primary efficacy endpoint for this Phase 3 registration trial will be increase in blood pressure. La Jolla plans to initiate this multicenter, randomized, double-blind, placebo-controlled, Phase 3 clinical trial pursuant to the approved SPA in the first quarter of 2015.

La Jolla Pharmaceutical Co. Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 05:30 PM

La Jolla Pharmaceutical Co. Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 05:30 PM. Venue: The Waldorf Astoria, New York, New York, United States. Speakers: George F. Tidmarsh, Chief Executive Officer, President, Principal Financial Officer, Principal Accounting Officer, Secretary and Director.

La Jolla Pharmaceutical Company and the George Washington University Announce Exclusive Worldwide License Agreement

On December 9, 2014, La Jolla Pharmaceutical Company entered into a Patent License Agreement, effective as of November 30, 2014, with The George Washington University (GW), under which GW exclusively licensed certain intellectual property rights, assigned to and controlled by GW, relating to the potential use of angiotensin II for the treatment of hypotension. The licensed intellectual property rights principally consist of three provisional patent applications filed in the United States, with worldwide rights to foreign filings on such application(s). The company is currently developing a proprietary formulation of angiotensin II (internally referred to as LJPC-501) for the treatment of catecholamine-resistant hypotension. Under the License Agreement, the company will pay a one-time license initiation fee of $250,000. In consideration for the continued use of the Patent Rights, the company is required to pay a nominal annual license maintenance fee. Upon the achievement of certain milestones relating to clinical approvals and the issuance of patents within the Patent Rights, the company will be required to pay milestone fees totaling up to $1,725,000 in the aggregate. Additionally, the company will be required to pay royalties on products covered by the Patent Rights (a Licensed Product), with such royalty rates ranging from the low- to mid- single digits. Commencing one year after the first commercial sale of a Licensed Product, the company will be required to pay escalating minimum annual royalty payments, up to the mid-six-figure range. Upon a sublicense of the Patent Rights to a third party, the company will be required to pay a portion of the sublicense revenue to GW, in a declining amount over a three-year period from execution of the License Agreement. The company will also be required to use commercially reasonable efforts to develop and commercialize one or more Licensed Products within certain pre-determined time periods set out the License Agreement.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LJPC:US $20.52 USD -0.275

LJPC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LJPC.
View Industry Companies
 

Industry Analysis

LJPC

Industry Average

Valuation LJPC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 6.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LA JOLLA PHARMACEUTICAL CO, please visit www.ljpc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.